ConductScience.org, home

Paper24201212

Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.

Flotte TR. Mol Ther, 2013. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. Papers, record 24201212. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24201212

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
PubMed
Journal
Mol Ther
PubMed
Year
2013
PubMed
Publication types
Historical Article, Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.49
iCite
Revised in PubMed
2021-10-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Flotte TRTerence R

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DependovirusMajor topic
Genetic TherapyMajor topic
Genetic VectorsMajor topic
Clinical Trials as Topic
Evolution, Molecular
History, 20th Century
History, 21st Century
Humans
National Institutes of Health (U.S.)
Phylogeny
United States

Source PubMed

Download CSV of topics

References100

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119953081Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.Mol Ther2010https://conductscience.org/library/papers/19953081PubMed
216076250Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy.Hum Gene Ther2005https://conductscience.org/library/papers/16076250PubMed
312954205Characterization of the adenoassociated virus Rep protein complex formed on the viral origin of DNA replication.Virology2003https://conductscience.org/library/papers/12954205PubMed
417115945Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.Hum Gene Ther2006https://conductscience.org/library/papers/17115945PubMed
514769732
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Chest2004https://conductscience.org/library/papers/14769732PubMed
69581911A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.Hum Gene Ther1998https://conductscience.org/library/papers/9581911PubMed
720606642A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.Mol Ther2010https://conductscience.org/library/papers/20606642PubMed
88773517A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease.Hum Gene Ther1996https://conductscience.org/library/papers/8773517PubMed
914325163ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.Science1965https://conductscience.org/library/papers/14325163PubMed
108151765Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels.J Virol1994https://conductscience.org/library/papers/8151765PubMed
1112162817A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.Hum Gene Ther2002https://conductscience.org/library/papers/12162817PubMed
127946381Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration.Am J Respir Cell Mol Biol1994https://conductscience.org/library/papers/7946381PubMed
132153052In vitro resolution of covalently joined AAV chromosome ends.Cell1990https://conductscience.org/library/papers/2153052PubMed
1411263951Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia.Exp Mol Pathol2001https://conductscience.org/library/papers/11263951PubMed
1519854499Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.Lancet2009https://conductscience.org/library/papers/19854499PubMed
1614965381Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.Hum Gene Ther2004https://conductscience.org/library/papers/14965381PubMed
176095038A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase.Mol Cell Biol1984https://conductscience.org/library/papers/6095038PubMed
188627804In vivo model of adeno-associated virus vector persistence and rescue.J Virol1996https://conductscience.org/library/papers/8627804PubMed
1910196295Gene therapy vectors based on adeno-associated virus type 1.J Virol1999https://conductscience.org/library/papers/10196295PubMed
2012716974Adeno-associated viruses undergo substantial evolution in primates during natural infections.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12716974PubMed

See all 100 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42278347Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization.Int J Mol Sci2026https://conductscience.org/library/papers/42278347PubMed
41257285Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/41257285PubMed
41179895AAV viral vectors as therapeutic interventions for inherited or non-inherited cardiac disorders: current aspects and future prospects.Front Med (Lausanne)2025https://conductscience.org/library/papers/41179895PubMed
40186350AAV vector development, back to the future.Mol Ther2025https://conductscience.org/library/papers/40186350PubMed
39225214Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases.Curr Gene Ther2025https://conductscience.org/library/papers/39225214PubMed
37310260Structural and Biophysical Analysis of Adeno-Associated Virus Serotype 2 Capsid Assembly Variants.J Virol2023https://conductscience.org/library/papers/37310260PubMed
36986717Gene Therapy for Regenerative Medicine.Pharmaceutics2023https://conductscience.org/library/papers/36986717PubMed
35297680Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus.Hum Gene Ther2022https://conductscience.org/library/papers/35297680PubMed
35283274Durability of transgene expression after rAAV gene therapy.Mol Ther2022https://conductscience.org/library/papers/35283274PubMed
34522582In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges.Acta Pharm Sin B2021https://conductscience.org/library/papers/34522582PubMed
28944281Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.Genes Dis2017https://conductscience.org/library/papers/28944281PubMed
28774883The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction.EMBO Mol Med2017https://conductscience.org/library/papers/28774883PubMed
28142241Probing the Link among Genomic Cargo, Contact Mechanics, and Nanoindentation in Recombinant Adeno-Associated Virus 2.J Phys Chem B2017https://conductscience.org/library/papers/28142241PubMed
27434683CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector.Mol Ther Nucleic Acids2016https://conductscience.org/library/papers/27434683PubMed
27362483CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.PLoS Pathog2016https://conductscience.org/library/papers/27362483PubMed
26305933Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction.Proc Natl Acad Sci U S A2015https://conductscience.org/library/papers/26305933PubMed
25091489State-of-the-art human gene therapy: part I. Gene delivery technologies.Discov Med2014https://conductscience.org/library/papers/25091489PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24201212

GET https://conductscience.org/api/papers/v1/24201212/references?page=2